Currently, the most clinically relevant immune checkpoints (ICPs) include CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and, in breast cancer, the PD-1 (programmed cell-death protein 1)/PD-L1 (programmed death-ligand 1) axis. This evidence concerns the gene CD274 and breast cancer.